Drug & intervention

erdafitinib

RxCUI 2123125

Clinical trials8
Recruiting0
Related conditions20
Synonyms1

RxNorm ingredient and formulation relationships

Source-verified product relationships. Every strength, delivery form and RxCUI remains a separate clinical concept.

Loading RxNorm relationships…

Clinical trials

8 shown
Erdafitinib for the Treatment of Patients With Castration-Resistant Prostate CancerNCT04754425 · 2021-07-15
TERMINATED
Erdafitinib and Abiraterone Acetate or Enzalutamide in Treating Patients With Double Negative Prostate CancerNCT03999515 · 2020-04-27
TERMINATED
FGFR Inhibitor in FGFR Dysregulated CancerNCT03827850 · 2019-03-25
TERMINATED
Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)NCT03210714 · 2018-06-05
ACTIVE_NOT_RECRUITING
Fulvestrant, Palbociclib and Erdafitinib in ER+/HER2-/FGFR-amplified Metastatic Breast CancerNCT03238196 · 2017-08-18
COMPLETED
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)NCT03155620 · 2017-07-31
ACTIVE_NOT_RECRUITING
A Study to Evaluate the Clinical Efficacy of JNJ-42756493 (Erdafitinib), A Pan-Fibroblast Growth Factor Receptor (FGFR) Tyrosine Kinase Inhibitor, In Asian Participants With Advanced Non-Small-Cell Lung Cancer, Urothelial Cancer, Esophageal Cancer Or CholangiocarcinomaNCT02699606 · 2016-07-08
COMPLETED
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)NCT02465060 · 2015-08-17
ACTIVE_NOT_RECRUITING

Conditions being studied

Advanced Malignant Solid Neoplasm3Recurrent Malignant Solid Neoplasm3Refractory Malignant Solid Neoplasm3Castration-Resistant Prostate Carcinoma2Recurrent Childhood Rhabdomyosarcoma2Recurrent Glioma2Recurrent Hepatoblastoma2Recurrent Langerhans Cell Histiocytosis2Recurrent Neuroblastoma2Recurrent Primary Central Nervous System Neoplasm2Recurrent Rhabdoid Tumor2Refractory Hepatoblastoma2Refractory Langerhans Cell Histiocytosis2Refractory Medulloblastoma2Refractory Neuroblastoma2Refractory Non-Hodgkin Lymphoma2Refractory Primary Central Nervous System Neoplasm2Refractory Rhabdoid Tumor2Stage IV Prostate Cancer AJCC v82Stage IVA Prostate Cancer AJCC v82

Drug identity and terminology: RxNorm. Trial relationships: ClinicalTrials.gov.